Literature DB >> 12011920

Vaccination of C57BL/10 mice against cutaneous Leishmaniasis using killed promastigotes of different strains and species of Leishmania.

Wilson Mayrink1, Gilmara Cristina dos Santos, Vicente de Paulo Coelho Peixoto de Toledo, Tânia Mara Pinto Dabés Guimaraes, George Luis Lins Machado-Coelho, Odair Genaro, Carlos Alberto da Costa.   

Abstract

Antigenic extracts from five Leishmania stocks were used to vaccinate C57BL/10 mice. The Leishvacin(R) and PH8 monovalent vaccine yielded the highest IFN-gamma levels in the supernatants of spleen cell culture from vaccinated animals. Each single strain immunized group showed evidence of protective immunity six months after the challenge with promastigotes of Leishmania (Leishmania) amazonensis. No differences were detected between the vaccinated groups. It can be concluded that vaccines composed of single Leishmania stocks can provide protection to C57BL/10 mice against L. (L.) amazonensis infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011920     DOI: 10.1590/s0037-86822002000200001

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

Review 1.  Leishmaniasis in humans: drug or vaccine therapy?

Authors:  Masoud Ghorbani; Ramin Farhoudi
Journal:  Drug Des Devel Ther       Date:  2017-12-22       Impact factor: 4.162

2.  MPLA and AddaVax® Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis.

Authors:  Diogo Oliveira-Maciel; Júlio Souza Dos-Santos; Gabriel Oliveira-Silva; Mirian França de Mello; Alessandra Marcia da Fonseca-Martins; Monique Pacheco Duarte Carneiro; Tadeu Diniz Ramos; Luan Firmino-Cruz; Daniel Claudio Oliveira Gomes; Bartira Rossi-Bergmann; Herbert Leonel de Matos Guedes
Journal:  Microorganisms       Date:  2021-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.